Michel 'Mike' Morency, Ph.D. is a lawyer practicing intellectual property, life sciences, patent services and 4 other areas of law. Michel 'Mike' received a Ph.D degree from McMaster University, and . Michel 'Mike' practices at Adler Pollock & Sheehan P.C. in Boston, MA.
Michel 'Mike' Morency, Ph.D.
Reviews for Michel 'Mike'
Have you consulted or hired this lawyer?
Leave a review about your experience with this lawyer.As President and CEO of NF2 BioSolutions, I would like to recommend Dr. Mike Morency without reservation to any organization seeking a strategic, hands‑on intellectual property and transactions leader who thinks like an operator and executes like a seasoned attorney. Few combine deep scientific fluency with seasoned transactional judgment the way Mike does. He initially represented an investor in our organization and now represents NF2 BioSolutions directly. Across both roles, he has consistently protected our mission and strengthened our position with the kind of practical, business‑forward counsel that moves therapies closer to patients. One moment in particular crystallized Mike’s diligence and integrity. During a collaborator’s patent filing, I was inadvertently omitted as an inventor on a patent family. Mike was the only professional who spotted the error. He moved methodically to correct the record and ensure that I was added as an inventor — an action that was not only legally
As co-founder of an early-stage biotech, I value working with Dr. Morency on IP and transactional matters critical to success and growth. Grounded in biomedical sciences and law, 'Mike' brings clarity to complex issues and translates highly technical innovations into strong, defensible IP assets. He guided us to build a cost-effective, strategically sound IP portfolio that would withstand rigorous due diligence. With a unique business-minded approach, Mike knows that, for emerging firms, IP is about protection AND leverage for financing/partnering/commercialization. His skill in structuring, negotiating, and executing licensing agreements and collaborative transactions is invaluable. Mike is a pleasure to work with, being detail-oriented, responsive, generous with his time, and fully committed to client success. His anticipation of challenges inspired confidence in our decisions and directions. I sincerely endorse him as a trusted, strategic partner for IP and transactional needs.
I’m pleased to recommend Dr. Mike Morency for his exceptional counsel in intellectual property strategy. He combines deep scientific expertise with sharp business acumen. As a registered U.S. patent attorney with a Ph.D. in Medical Sciences, Mike translates complex science into clear, defensible IP that aligns with strategic goals—whether for financing, partnerships, or market access. He takes the time to explain IP strategy, enabling informed, high-impact decisions across technical, legal, and commercial teams. With over 30 years of experience guiding life-science innovators from discovery to commercialization, Mike has helped evaluate and protect core inventions, assess risks, and structure agreements that accelerate development while preserving long-term value. His counsel is pragmatic and cost-effective, focusing on what truly matters. Responsive, composed, and proactive, Mike is a true partner—candid, outcome-driven, and deeply committed. I recommend him without hesitation.
As COO of Pyros, I retained Dr. Michel “Mike” Morency to evaluate and negotiate a license on a PCT. His assessment was unsparing and invaluable: the pending claims were unpatentable over the prior art, foreign rights were not pursued beyond the U.S., and the risk of thin exclusivity was high. Instead of walking away—or overpaying—Mike engineered a pragmatic licensing structure. He limited the field of use and crafted an escalating economic framework tied to patent outcomes: least compensation if no patents issued, stepping up only if patent protection were achieved. He also secured prosecution control for Pyros so the strategy served our timelines, not the licensor’s. That combination let us unlock freedom to operate while preserving capital. Mike’s counsel didn’t stop at the paper. He re-scoped the claim set to overcome prior art and then drove a focused prosecution path that culminated in an issued U.S. patent.
I have known and worked with Mike for over 20 years, first as a mentor at a Boston-based law firm, then as an outside counsel when I worked for a large, multi-national biopharmaceutical company, and now as a colleague at Adler, Pollock & Sheehan, PC. Mike is an excellent attorney. He has an uncanny ability to elevate the effectiveness of the people who work with him. Early in my career, Mike was always available to help and to patiently teach junior professionals, while listening to and valuing their input. As outside counsel, Mike always put the best professionals for each project, to produce a high-quality but cost-effective product. Now, later in my career, I enjoy and value working with Mike as a colleague. With his broad-based experience in both intellectual property and transactional matters, Mike is an invaluable resource to my colleagues and me.
I have worked with Mike as my patent attorney in several life science companies for more than 15 years, from startups to publicly traded companies. From our initial meeting, I got the sense that Mike had a very personal approach to working with his clients and was not looking at simply obtaining another client from whom he could extract business. Given his tremendous experience and extensive technical background, he not only understands complex technologies but he is also able to think outside of the box and always comes up with creative solutions. In addition to his skills in intellectual property, Mike also has an extensive understanding of the commercialization of life science technologies and he excels at harmonizing a company's intellectual property assets with its business objectives. I will definitely continue to use Mike for all of my IP related needs and I recommend others to consider him as well.
Services
Areas of Law
Practice Details
-
Firm InformationPositionRegistered Patent AttorneyFirm NameAdler Pollock & Sheehan P.C.
-
Representative Cases & TransactionsCasesRepresentative Matters: Advising life science companies on the creation
development of patent portfolios, collaborative research, licensing of technology, raising money through venture capital
other financial transactions,
enforcement of their intellectual property rights.
Advising university technology licensing offices on assessing industry interest in their technologies
the strength of intellectual property covering the same in order to direct resources towards technologies with greater commercialization potential.
Negotiating
drafting numerous option agreements, licensing agreements, sponsored research agreements, cooperative research agreements on behalf of life science companies acquiring intellectual property rights from universities
non-profit research organizations.
Providing patent invalidity, freedom to operate
non-infringement opinions
Counseling life science companies in patent interference, post-grant reviews, intellectual property enforcement,
litigation issues.
Performing due diligence investigations for private
public financings
M&A transactions.
Negotiating
drafting various transactional agreements for life science companies including manufacturing
supply agreements, licensing agreements, distribution agreements, material transfer agreements, clinical trial agreements, confidentiality agreements, consulting agreements,
various services agreements.
Representative Transactions
Financings: Mergers & Acquisitions (M&A): Represented a privately-held specialty pharmaceutical company in an acquisition by a publicly-traded NASDAQ pharmaceutical company for $125 million USD plus milestones.
Represented a privately-held biomedical cancer therapeutic company in an acquisition/asset purchase by a publicly-traded NASDAQ biotech company for $55.3 million USD.
Represented a publicly-traded NASDAQ biopharmaceutical company focused on rare pediatric
orphan diseases, in an acquisition of another publicly-traded NASDAQ biopharmaceutical company in an all-stock transaction valued at over $15 million USD, plus contingent value rights CVRs for up to an additional $6.5 million USD in subsequent payments.
Represented a private, pre-clinical medical technology company in the sale of its royalty rights to a major institutional investor for $8 million USD.
Represented a publicly-traded NASDAQ regenerative medicine company in the merger with two privately-held biotech companies to form a new publicly-traded NASDAQ regenerative medicine company.
Strategic Collaborations / Licensing: Represented a privately-held biomedical diagnostic company in a multi-year, worldwide Distribution Agreement with a Fortune 500 healthcare company.
Represented a publicly-traded NASDAQ genomics company in a Collaboration Agreement with a Fortune 500 pharmaceutical company worth over $1.5 billion USD.
Represented a privately-held biotech regenerative medicine company in an Exclusive Licensing Agreement with a Fortune 500 pharmaceutical company worth over $125 million USD, with $15 million USD upon signing.
Represented a subsidiary of a publicly-traded TYO pharmaceutical company in a Sponsored Research Agreement
an Exclusive License Agreement with an American university.
Represented a privately-held drug delivery company in an Exclusive License Agreement with a non-profit research hospital.
Represented a privately-held oncology company in a multi-year Cooperative Research
Development Agreement (CRADA) with the National Cancer Institute.
Initial Public Offerings (IPOs) / Financings: Represented a privately-held specialty pharmaceutical company in an IPO on NASDAQ for $70 million USD.
Represented the underwriters in the IPO of a privately-held molecular diagnostic company on NASDAQ for $82.5 million USD.
Represented the underwriters in the IPO of a privately-held biotechnology company on TSX for $42.4 million CDN, representing the largest Life Sciences IPO in Canada at the time.
Represented a publicly-traded NASDAQ biopharmaceutical company in a bond deal priced at $150 million USD.
Michel 'Mike' Morency, Ph.D.
175 Federal Street, 10th FloorBoston, MA 02110U.S.A.
Show on map